Arena Pharmaceuticals (ARNA) Surges on VIVUS's (VVUS) Day
Tweet Send to a Friend
Up)
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) is surging higher Friday although no fundamental reason can be found to explain the action.
Rival VIVUS Inc. (Nasdaq: VVUS) is expected to receive FDA approval today, but this is for a erectile dysfunction drug avanafil and is not related to competing obesity drug Qnexa.
Shares of Arena Pharmaceuticals last traded at $2.74, up 27%.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Rival VIVUS Inc. (Nasdaq: VVUS) is expected to receive FDA approval today, but this is for a erectile dysfunction drug avanafil and is not related to competing obesity drug Qnexa.
Shares of Arena Pharmaceuticals last traded at $2.74, up 27%.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Tesla (TSLA) Ramps Higher (GM)
- Apollo (APO) Said to Be in Second Round Bidding for Rio's (RIO) Iron Ore Co. of Canada Unit
- Arena Pharmaceuticals (ARNA) Weakens Mid-Day
Create E-mail Alert Related Categories
Momentum Movers, Trader Talk
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
